Hundreds to Go

Pharmaceutical company Sanofi-Aventis is eliminating “hundreds of jobs,” reports Ed Silverman at Pharmalot. The cuts come in the wake of Sanofi’s acquisition of Genzyme, he say, adding that some R&D operations will be shuffled between its New Jersey and Massachusetts sites, and that there will be layoffs in sales, particularly in the cardiovascular and oncology groups.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.